Guest Column | June 18, 2026

Why Your LATAM Authorized Representative Strategy Is A Market Entry Decision, Not A Clerical One

By Julio G. Martinez-Clark, CEO, bioaccess

Columbia and brazil flags together-GettyImages-1089427714

The most expensive decision a U.S. medical device company makes in Latin America is rarely the one its leadership team has on the agenda.

It is not the choice of country. It is not the product registration pathway. It is not the price point. It is the single line item buried somewhere on page 14 of a market entry deck that reads “Local Authorized Representative — TBD.”

That blank, filled in casually after the strategy is set, is where commercial control either gets preserved or quietly handed away. Across Argentina, Brazil, Colombia, Mexico, and the smaller Latin American device markets, the entity that holds or manages the regulatory asset becomes the operational choke point for everything that happens next: importation, renewals, post-market vigilance, product changes, partner transitions, and commercial leverage.1 In some markets, the distributor relationship can quietly become the entire market entry architecture.

The reason this decision keeps getting filed away as administrative is that it does not feel strategic when the company is small and the registration is the goal. It feels strategic the day the manufacturer decides to switch distributors, expand into a second country, sell the LATAM asset, or recall a product. By then, the architecture is set.

This piece argues that the local representative or registration holder decision deserves a seat at the strategy table before registration begins. Below is how to think about it.

What An Authorized Representative Actually Owns

In most of Latin America, the regulator does not allow a foreign manufacturer to hold a medical device registration directly. Instead, the registration is issued to a local legal entity that acts on the manufacturer’s behalf. That entity is variously called the authorized representative, the registration holder, or the titular del registro, depending on the country and the regulatory framework.1,2 Mexico calls it the representante legal or titular del registro sanitario under COFEPRIS.3 Brazil’s ANVISA issues the registration to a Brazilian detentor do registro.5 Argentina’s ANMAT issues to a local representante autorizado.6 Colombia is the structural exception across the region: INVIMA permits the foreign manufacturer to hold the Registro Sanitario title directly, provided the manufacturer designates a representante legal — an entity or individual domiciled in Colombia who acts as the local point of legal contact for the regulator.4 These are not just names on paperwork. With the limited exception of Colombia, they are the legal owners of the regulatory record in that jurisdiction.

This matters because in the markets where the holder is a third party, the registration is transferable only with the holder’s cooperation.2 If your distributor holds the registration in their name and you decide to leave them, you do not simply walk the registration over to a new partner. You enter a negotiation. In some markets, you enter a renewal cycle. In others, you start the registration process over from scratch.

The same holder almost always controls the import permit. They almost always handle post-market vigilance reports to the regulator. They are often the point of contact for product change submissions, recall notifications, and renewal filings.2,5 The further your relationship with that entity goes, the more your commercial flexibility narrows.

The Five Control Vectors That Move With The Registration

When a manufacturer signs the agreement that places the registration in a partner’s name, five separate things move with it.

  • Regulatory asset ownership. The registration itself is an asset on a balance sheet — your company’s, the partner’s, or contested. In most LATAM markets, the asset sits with the partner unless the contract explicitly says otherwise.1,2 Sale of business and merger and acquisition events depend on who can transfer the asset. If you ever intend to sell your LATAM operation, the registration holder becomes a counterparty to that transaction.
  • Import continuity. The entity that holds the import permit decides when, how often, and in what quantity your device crosses the border.7 A distributor who is also the registration holder has the structural ability to slow imports if the commercial relationship sours. This is not a hypothetical. It is the leverage that experienced distributors price into their first contract.
  • Post-market obligations. Adverse event reporting, field safety notices, and recall coordination are the registration holder’s regulatory obligation.5,8 The regulator talks to them, not to you. If your relationship with that holder degrades, your visibility into the post-market environment degrades with it. Worse, your ability to respond quickly to a regulator inquiry can be filtered through a partner whose incentives may have shifted.
  • Distributor leverage. In LATAM, the registration holder and the distributor are frequently the same legal entity.1 Most U.S. manufacturers do not realize this until they want to add a second distributor or change distribution terms. The original distributor’s leverage is not their contract. It is their control of the registration. They can structurally refuse to allow a parallel partner without giving up the registration first.
  • Future commercialization flexibility. Adjacent-product registrations, line-extension registrations, software as medical device add-ons, and digital companion submissions all benefit from being filed against an existing dossier.2 If that dossier is owned by a partner whose interests are no longer aligned with yours, every adjacent product becomes a fresh negotiation rather than a streamlined add-on.

Each of these five vectors looks manageable in isolation. They compound dangerously when concentrated in a single partner.

The Three Architectures, And What Each Locks You Into

Most U.S. medical device manufacturers entering LATAM choose, often without realizing they are choosing, one of three architectures.

  • Architecture A: Distributor-as-holder. The local distributor takes the registration in their name. This is the fastest path to market and the cheapest at the moment of registration.9 It is also the most leveraged against you in every subsequent decision. If your strategic intent is to test market demand for 18 to 24 months and then exit if results are weak, this architecture is defensible. If your strategic intent is to build a long-term LATAM commercial presence, this architecture is the trap.
  • Architecture B: Independent authorized representative. A specialist third party — a regulatory affairs consultancy, a clinical research organization with a regulatory practice, or a dedicated authorized representative firm — holds the registration on your behalf under a service contract.9 They have no commercial conflict because they do not distribute the product. They charge a fee, typically annually. The architecture preserves your distributor flexibility and your registration mobility. It costs more on day one and less every year after.
  • Architecture C: Own legal entity. The manufacturer establishes a local subsidiary or branch and registers the device in the subsidiary’s name. The control is total. The setup cost is meaningful — local incorporation, tax registration, accounting, sometimes a local employee — and the carrying cost compounds. The architecture is correct for manufacturers with confirmed LATAM revenue at scale or for those preparing the LATAM business for divestiture as a stand-alone asset.

The strategic mistake is not choosing wrong. The strategic mistake is choosing by default, letting the registration vendor present the path of least resistance, and only realizing two years later that the architecture has set the ceiling on what your LATAM business can become.

What Country-Level Texture Actually Matters

A country-by-country regulatory checklist is the wrong artifact for this decision. The right artifact is a country-by-country leverage profile.

Mexico (COFEPRIS)

The titular del registro sanitario must be a Mexican legal entity, governed by the Reglamento de Insumos para la Salud and the Acuerdos that COFEPRIS issues to operationalize it.3 COFEPRIS permits the holder to be different from the distributor, but in practice many distributors prefer to hold the registration to lock in the supply relationship. Mexico’s ongoing migration of submissions to the DIGIPRiS digital platform is compressing approval timelines and electronic interaction with the regulator, which is making the registration itself more valuable — and the holder relationship correspondingly more leveraged.10

Brazil (ANVISA)

The detentor do registro must be Brazilian.5 Brazil enforces particularly strict post-market (technovigilance) reporting and recall coordination through the registration holder under RDC 67/2009 and the broader Sistema Nacional de Tecnovigilância, which means the holder’s competence and reliability matter operationally as much as their commercial alignment.8,11 The technovigilance regime is among the most prescriptive in Latin America, and a registration holder that is slow or unsophisticated on field safety notices, recall execution, or change submissions can expose the manufacturer to enforcement risk independent of the underlying product.

Colombia (INVIMA)

Colombia is the only Latin American country in which the foreign manufacturer can hold the Registro Sanitario directly. The current framework is Decreto 4725 de 2005, which governs the sanitary registration, commercialization, importation, and surveillance regime for medical devices for human use, complemented by Decreto 3770 de 2004 for in vitro diagnostic reagents.4,12 The manufacturer still needs a representante legal — an entity or individual domiciled in Colombia who serves as the local point of legal contact for INVIMA — but the registration title itself can stay with the manufacturer. This structural difference matters strategically: In Colombia a manufacturer can replace its representante legal without losing or transferring the registration, which materially weakens the kind of distributor leverage that exists in Mexico, Brazil, and Argentina. The operational corollary is that the manufacturer’s diligence sits less on the regulatory architecture and more on the contractual terms negotiated with whichever representante legal it selects — including renewal coordination obligations, post-market vigilance escalation, and the ability to transfer the role on commercially reasonable notice.13

Colombia’s framework is also entering a generational modernization. The Ministry of Health has been structuring a new Decreto Único de Dispositivos Médicos e In Vitro that is expected to replace both Decreto 4725 de 2005 and Decreto 3770 de 2004, unifying medical devices and in vitro diagnostic reagents — now formally termed Dispositivos Médicos de Diagnóstico In Vitro, or DMDIV — under a single regulatory architecture.15 The draft framework introduces three authorization mechanisms (notificación sanitaria for low and moderate risk, registro sanitario for high and very high risk, and permiso de comercialización) and adopts the four-tier risk classification of the International Medical Device Regulators Forum (IMDRF). For U.S. manufacturers, the most strategically relevant element is the formal incorporation of reliance pathways that allow INVIMA to recognize approvals from highly vigilant international authorities more quickly, alongside explicit regulation of Software as a Medical Device (SaMD) and codification of ISO 13485 (or local equivalents) as the validated quality management system standard.15 The new regime is not yet enacted, but manufacturers structuring 2026 to 2027 market entry decisions should plan for both the current Decreto 4725 framework and the architectural shift the unified decree will introduce.

Argentina (ANMAT)

ANMAT issues the medical device registration to a local representante autorizado, established under Disposición 2318/2002 and its subsequent amendments that govern device classification, registration, and post-registration changes.6 Argentina’s commercialization economics improved materially in 2026 — Disposición 2978/2026 cut import tariffs on medicines and medical devices by 50 to 70 percent effective June 1, 2026, reducing the per-unit landed cost of imported devices.14 This makes Argentine market entry more attractive on a unit economics basis but does not change the structural requirement for a local representative. The manufacturer choosing among distributor-as-holder, independent representative, or local subsidiary still faces the same leverage trade-offs — just over a more favorable cost base.

The texture matters because it shapes the bargaining position of your local partner. A representante legal in Colombia sits in a market where the manufacturer retains registration ownership, which structurally caps the partner’s leverage.4,12 A detentor do registro in Brazil sits inside a prescriptive technovigilance regime that elevates the operational competence of the partner above almost every other consideration.8,11 A titular in Mexico sits in a market where digital reform is increasing the registration’s strategic value year over year.10 An authorized representative in Argentina sits in a market where the recent import tariff reduction has increased the unit economics of the underlying business.14 Your contractual leverage with each is materially different, even if the contract templates look identical.

A Decision Framework Worth Putting On The Page

For manufacturers evaluating LATAM market entry, three questions surface the right architecture before the registration starts.

  • Question 1: How long do you intend to stay? If the answer is two years or less, distributor-as-holder may be acceptable. If the answer is five years or more, distributor-as-holder is almost always wrong. Three to five years is the gray zone where independent authorized representatives earn their fee.
  • Question 2: How many products do you plan to register in this country? A single-product manufacturer can absorb the cost of switching architectures later. A multi-product manufacturer cannot. If your road map calls for line extensions, software companions, or adjacent device categories within 36 months, your architecture needs to support adding registrations to the same dossier without renegotiating the holder relationship from zero each time.
  • Question 3: How concentrated is your commercial dependence on this country? If LATAM is a sub-5 percent revenue line, distributor-as-holder is a defensible operational shortcut. If LATAM is 15 percent or more of your revenue, or your strategic plan calls for LATAM to become 15 percent or more, the registration holder is too leveraged a position to assign to your distributor.

The framework is not novel. It is the kind of question set that gets asked rigorously for U.S. distribution agreements and casually for LATAM ones. That asymmetry is exactly the problem.

The Takeaway For Strategy Teams

In the next 12 months, more U.S. medical device manufacturers will enter LATAM through leaner local models than at any point in the past decade. Distributor-led, third-party-led, and lean-subsidiary models are all proliferating.9 The capital efficiency story is real. The regulatory environment in several major LATAM markets is genuinely improving.15 The opportunity is genuine.

What is also genuine is that the structural decisions made at market entry — particularly the decision of who holds the regulatory asset — will determine which manufacturers grow into long-term LATAM franchises and which find themselves locked into early commercial choices they cannot reverse without starting over.

The authorized representative line item belongs in the strategy deck, not the appendix. The clearest sign that a manufacturer has understood this is that the person responsible for it sits next to the BD lead in the planning meeting, not three reports removed from them.

The most expensive decision is rarely the one on the agenda. In Latin America, it is almost always the one that looks like a clerical step until the day it does not.

References

  1. Authorized Representatives in Latin America for Medical Devices. Emergo by UL. [Online] 2025. [Cited: June 7, 2026.] https://www.emergobyul.com/services/authorized-representative.
  2. Establishing Local Authorized Representatives in Latin America: A Strategic Guide. Global Regulatory Partners. [Online] 2024. [Cited: June 7, 2026.] https://globalregulatorypartners.com/services/authorized-representative-services/.
  3. Reglamento de Insumos para la Salud — Título Octavo, Dispositivos Médicos. Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). [Online] 2024. [Cited: June 7, 2026.] https://www.gob.mx/cofepris/acciones-y-programas/dispositivos-medicos.
  4. Dispositivos Médicos y Otras Tecnologías — Registro Sanitario. Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). [Online] 2025. [Cited: June 7, 2026.] https://www.invima.gov.co/dispositivos-medicos-y-otras-tecnologias.
  5. Resolução RDC nº 751/2022 — Classificação, Regularização e Notificação de Dispositivos Médicos. Agência Nacional de Vigilância Sanitária (ANVISA). [Online] September 15, 2022. [Cited: June 7, 2026.] https://www.gov.br/anvisa/pt-br.
  6. Disposición 2318/2002 — Reglamento Técnico Mercosur sobre Registro de Productos Médicos. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). [Online] 2002. [Cited: June 7, 2026.] https://www.argentina.gob.ar/anmat/regulados/productos-medicos.
  7. Latin America Medical Device Importation: Regulatory Pathway Considerations. RegDesk. [Online] 2024. [Cited: June 7, 2026.] https://www.regdesk.co/latin-america-medical-device-regulation/.
  8. ANVISA Updates Medical Device Postmarket Rules. Trench Rossi Watanabe. [Online] April 12, 2024. [Cited: June 7, 2026.] https://www.trenchrossi.com/en/legal-alerts/.
  9. Market Entry Models for Medical Devices in Latin America: Distributor, Third-Party, and Subsidiary Comparison. Mattos Filho. [Online] December 6, 2024. [Cited: June 7, 2026.] https://www.mattosfilho.com.br/en/.
  10. Plataforma DIGIPRiS — Digitalización de Trámites para Dispositivos Médicos. Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). [Online] 2026. [Cited: June 7, 2026.] https://digipris.cofepris.gob.mx/.
  11. Resolução RDC nº 67/2009 — Sistema Nacional de Tecnovigilância. Agência Nacional de Vigilância Sanitária (ANVISA). [Online] December 21, 2009. [Cited: June 7, 2026.] https://www.gov.br/anvisa/pt-br/assuntos/tecnovigilancia.
  12. Decreto 4725 de 2005 — Régimen de Registros Sanitarios, Permisos de Comercialización y Vigilancia Sanitaria de los Dispositivos Médicos para Uso Humano. Ministerio de la Protección Social de Colombia. [Online] December 26, 2005. [Cited: June 7, 2026.] https://www.invima.gov.co/documents/20143/453029/Decreto+4725+de+2005.pdf.
  13. Medical Device Registration in Colombia: Process Considerations for Foreign Manufacturers. Emergo by UL. [Online] 2025. [Cited: June 7, 2026.] https://www.emergobyul.com/resources/colombia-process-chart.
  14. Disposición 2978/2026 — Reducción de Aranceles de Importación para Medicamentos y Productos Médicos. Boletín Oficial de la República Argentina. [Online] May 19, 2026. [Cited: June 7, 2026.] https://www.boletinoficial.gob.ar/detalleAviso/primera/342122/20260519.
  15. Hacia un Nuevo Régimen Único de Dispositivos Médicos y Reactivos de Diagnóstico In Vitro en Colombia. ConsultorSalud. [Online] 2026. [Cited: June 7, 2026.] https://consultorsalud.com/regimen-unico-dispositivos-medicos-impactos/.

About The Author:

Julio G. Martinez-Clark is co-founder and CEO of bioaccess, a market access consultancy that works with medical device companies to help them do early-feasibility clinical trials and commercialize their innovations in Latin America. Julio is also the host of the Global Trial Accelerators podcast. He has a bachelor's degree in electronics engineering (BSEE) and a master's degree in business administration (MBA).